Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of ipilimumab plus dacarbazine versus dacarbazine with placebo in untreated stage IIIc/IV melanoma
2005-006082-14Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Ipilimumab + dacarbazine with Placebo + dacarbazine (2 arms). Primary endpoint: Progression-free survival. Started Jun 2006; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2005-006082-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006082-14.